



BioSig[™]
technologies

NASDAQ: BSGM

Disclaimer

This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new products, market acceptance of BioSig's products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig's control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig's products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig's ability to effectively react to other risks and uncertainties described from time to time in BioSig's SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Mission

Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology, **BioSig Technologies** is committed to addressing healthcare's greatest priorities — saving time, saving costs, and saving lives.

With its **PURE EP™** product platform, the company aims to improve physician **workflow efficiency** and **efficacy** *while decreasing cost per case*.

By uncovering never-before-seen **clarity** of cardiac signals, **PURE EP™** opens the door to breakthrough innovations in the field of electrophysiology.


BioSig Today

- Significant secular tailwinds
- Substantial and Growing TAM
- First Customers are Industry Leaders
- Commercial launch with new team– July 2022
- Strong clinical data supporting commercialization
- Substantial and growing IP patent portfolio
- Recent M&A highlights potential value



Secular Tailwinds

- \$12.2 billion Global EP market by 2026, estimated 13.5% CAGR*
 - Projected 12.1 million AFib sufferers in US in 2030
 - Aging population of 65+
 - Studies show ablation as effective first-line treatment
 - Increasing patient preference for ablation
 - Resumption of elective surgeries post COVID



World Health Organization

Market Opportunity | PURE EP™

Global EP Procedures Growing Rapidly



Experience in Well-Respected Healthcare Institutions



MIDWEST HEART
& VASCULAR SPECIALISTS

TEXAS CARDIAC ARRHYTHMIA INSTITUTE

St. David's Medical Center

Advancing Commercialization

BioSig's Approach

Phase 1



Selective Installations
~ **7 centers**
Learning, fixing, improving
2019-2020

Phase 2



Expansion 17 centers
Clinical trial, peer review
publication, initial sales
2021-2022

Phase 3



National sales team expansion
GPO/ IDN development
2022

Phase 4



National, full-scale rollout
2023 →

New Management: Strong Industry Experience



Ken Londoner
Chief Executive Officer



Gray Fleming
Chief Commercial Officer




CCO and COO have almost 40 years of combined experienced at St. Jude/Abbott and have been responsible for \$5B of medical device sales



John Sieckhaus
Chief Operating Officer

Sales Geography – Nationwide Rollout



Expanded Purchase Options

Capital Purchase



Company Rental



Operational Lease



PURE EP™ System | Customer Installation



PURE EP™



Texas Cardiac Arrhythmia Institute

Strong Clinical Data

PURE EP 2.0

Signals from 51 patients undergoing any ablation procedure

Multi-center (TCAI, Mayo, & MGH)

STUDY OBJECTIVE

To determine the clinical value of the PURE EP signal when compared to conventional sources

RESULTS


Cumulatively, 75.2% of PURE EP signals rated as superior to conventional systems.

PURE EP signals were **statistically rated as superior in (3) different categories:**

- Overall signal quality - 73% superior
- Ability to discern NF vs FF – 83% superior
- Small fractionated signals of clinical interest - 73% superior

PUBLICATION

September 2021 Journal of Cardiovascular Electrophysiology



Patent Portfolio

Worldwide Fundamental Patents Granted/Allowed	19
Pending Applications in the US	11
Applications Currently Pending in Europe	6
New Applications Currently Being Drafted	1
Worldwide Design patents granted / Allowed	30

Selected Transactions

M&A Analysis:	Acquired	Value	Acquirer
Acutus	2022	50.0*	Medtronic
Affera, Inc.	2022	925.0	Medtronic
Baylis Medical Co., Inc.	2021	1750.0	Boston Scientific
Farapulse	2021	387.0	Boston Scientific
EPD Solutions	2018	538.0	Philips
HeartWare International	2016	1019.9	Medtronic
Topera Inc.	2014	250+	Abbott
Endosense SA	2013	333.8	St. Jude
Bard EP (C.R. Bard, Inc.)	2013	275.0	BD
Rhythmia Medical	2012	410.0	Boston Scientific

Recent Transactions

Medtronic purchased Acutus's Left-Heart Access Portfolio for \$50mm -Additional \$37mm pending milestones

Co-founded in 2018 by Jim Walker and John Strong, Healthcare industry veterans, ASPI brings deep expertise in commercialization, supply chain, contract management & execution, and value proposition optimization.

MARKET READINESS

- Go-to-Market Strategy
- Economic Value Modeling
- Pricing Strategy & Programs

ACCESS

- IDN & Hospital Strategy
- GPO Engagement
- Value Analysis Committee – Content & Execution

SALES ENGAGEMENT

- IDN & GPO Contracting
- Contract Execution
- Revenue Management

Our World Class Manufacturing Partner

\$3B+

Annual revenue

10,000

Employees

PLEXUS®

40%

Total revenue generated
from the Healthcare & Life
Sciences sector

600

Design & Development
Engineers

BioSig Presents at Industry Conferences 2022

- Kicked off HRS in May and KCHRS in August with compelling physician presentations.
- Platinum Sponsor at Cleveland Clinic Global EP Summit
- Very engaging exhibition areas and pipeline discovery meetings
- Emerged from events with tens of validated commercial leads



Key References (April 2022)



Optimizing Signals in the EP Lab

Amin Al-Ahmad, MD (Cardiac electrophysiologist - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – Great Debates and Updates in EP - March 2022.

[Click here to open](#)

Complex AF Case Study Utilizing a New Standard in Signal Processing

Dhanunjay Lakkireddy, MD (Executive Medical Director, Kansas City Heart Rhythm Institute, Overland Park, KS - USA) – January 2022 - 27th Annual International AF Symposium

[Click here to open](#)

Incorporating Advanced Intracardiac Signal Information Into the Clinical Workflow

G. Joseph Gallinghouse, MD (Texas Cardiac Arrhythmia Institute, - Austin, TX – USA) – December 2021 - [Click here to open](#)

PURE EP™ - From Clinical Data to Clinical Applications

Wendy Tzou, MD (University of Colorado Denver, CO.), Andrea Natale, MD and Amin Al-Ahmad, MD (Cardiac electrophysiologists - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – Live Roundtable Webinar – Nov. 2021.

[Click here to open](#)

Evaluation of a Novel Cardiac Signal Processing System for Electrophysiology Procedures: The PURE EP 2.0 Study

- Al-Ahmad A, Knight B, Tzou W, et al. - J Cardiovasc Electrophysiol.

2021;32(11):2915-2922. Epub 2021 Oct 1. doi: 10.1111/jce.15250.

[Click here to open](#)

PURE EP™ - A New Standard in Signal Processing

Amin Al-Ahmad, MD (Cardiac electrophysiologist - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – KC HRS 2021 - August 2021.

[Click here to open](#)

From Clinical Data to Clinical Applications

Christopher McLeod, MB, ChB (Cardiac electrophysiologist – Mayo Clinic - Jacksonville, FL – USA) – HRS 2021 – Non-CME Satellite Symposium - July 2021 - [Click here to open](#)

The Evolution of Intracardiac Signal Acquisition and Processing in Today's EP Lab Environment

Interview with Amin Al-Ahmad, MD (Cardiac electrophysiologist - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – Great Debates & Updates in Electrophysiology - April 2021. - [Click here to open](#)

Improved Intracardiac Signal Visualization During Cryo and RF Procedures

Deepak Gaba, MD (Cardiac electrophysiologist – Memorial Hospital, South Bend, IN – USA) - April 2021. shares his views on how the PURE EP™ System can help be more efficient and how high-fidelity signals can improve clinical outcomes - [Click here to open](#)

Benefits of the PURE EP™ System in Identifying and Interpreting Low Amplitude Signals

G. Joseph Gallinghouse, MD (Texas Cardiac Arrhythmia Institute, - Austin, TX – USA) – January 2021 - 26th International Annual AF Symposium.

Hyperlink to access resources: [Click here to open](#)

Further Optimizing Electrogram Signal Quality in the EP Lab

Bradley P. Knight, MD, FACC, FHRS (Professor of Medicine and Director of EP - Northwestern University, Chicago, IL - USA) – January 2021 - [Click here to open](#)

Advanced signal acquisition help drive procedural efficiency and efficacy

Raffaele Corbisiero, MD, EPS and Pedram Kazemian, MD (Deborah Heat and Lung Center, Browns Mills, New Jersey – USA) EP Lab Digest – December 2020 - [Click here to open](#)

VT in NICM by Pasquale Santangeli, MD, PhD - University of Pennsylvania Health System, Philadelphia, PA – USA – November 2020

Hyperlink to access resources: [Click here to open](#)

PURE EP case review on how high-fidelity intracardiac signals can help visualize conduction pathways faster - Andrea Natale, MD, FACC - Austin, TX – USA – September 2020 - [Click here to open](#)

ESC 2020: A novel cardiac signal processing system for electrophysiology procedures: early insights from the pure ep 2.0 study - [Click here to open](#)

Cardiac Signal Acquisition and Clinical Considerations for Accurate Interpretation

Samuel J. Asirvatham, MD (Mayo Clinic, Rochester, Minnesota, USA) and K. L. Venkatachalam, BSEE, M.D. (Mayo Clinic, Jacksonville, FL, USA) - HRS Science 2020 – June 12, 2020.

[Click here to open](#)

Cardiac signal acquisition and clinical implications of applying filters

Samuel J. Asirvatham, MD (Mayo Clinic, Rochester, Minnesota, USA) and K. L. Venkatachalam, BSEE, M.D. (Mayo Clinic, Jacksonville, FL, USA) - HRS Science 2020 – July 1, 2020

[Click here to open](#)

PURE EP™ is addressing critical unmet needs - Frequency Bandwidth and Linear Signal Acquisition

Dr Venkatachalam's presentation (Mayo Clinic, Jacksonville, FL - USA) – May 2020 -Stanford Biodesign New Arrhythmia Technologies Retreat - [Click here to open](#)

Shaping the Future of EP Through Advanced Signal Processing and Analysis

Andrea Natale, MD, FACC (St David's Medical Center, Austin, TX – USA) and Matthew Dare, CEPS – April 2020 - [Click here to open](#)

For more information, please contact:

Andy Ballou

VP of Investor Relations

BioSig Technologies, Inc.

55 Greens Farms

Westport, CT 06880

aballou@biosigtech.com

203 409-5444, x133